By using techniques in the laboratory, it is now possible to prepare 
and modify human DNA or genetic material which can be transferred to your 
cells in the laboratory. We will genetically modify cells which are the 
target of HIV infection, called T cells. We have prepared a gene delivery 
vehicle, either DNA or a viral vector, which contains an altered form of 
an AIDS virus gene, called Rev M10. When Rev M10 is expressed in 
lymphocytes in the laboratory, it provides protection against AIDS virus 
infection. This protein causes the cells which will contain it to block 
growth of the virus. The purpose of our study is to determine whether 
this gene therapy treatment will prolong the survival of T cells which 
contain this protective gene in your body. 
Alternative Therapies 
There are no known cures for patients with your disease. Other 
alternative treatments available to you include medication, such as AZT or 
ddl, to inhibit viral replication. Medical, surgical, or radiation 
treatment can be used on occasion to treat reversible complications. 
Other experimental treatments are under investigation which attempt to 
inhibit virus growth or to stimulate your immune system to reject your 
tumor, and you can be referred to physicians who are conducting such 
trials. In some cases, proteins are injected which can stimulate the 
immune system. You also have the option to receive no treatment at this 
time. 
Procedures 
Before receiving this treatment, you will receive many tests to see 
if you qualify for this study. These tests will be made either as an 
inpatient or an outpatient. These tests include: 1) blood tests 2) x- 
rays of the chest and 3) a blood test for the antibodies to Human 
Immunodeficiency Virus (HIV) , which causes AIDS. 
If you qualify for this study, we will take a blood sample from you, 
isolate your T cells, and genetically modify them in the laboratory. 
These cells will then be returned to you through a tube connected to a 
needle inserted into your vein. At different times in the protocol, blood 
samples will be taken, and the survival of these genetically modified 
cells will be assessed. This procedure will be performed prior to 
treatment and at intervals of 2 weeks up to 1 year. 
RISKS AND SIDE EFFECTS 
There are potential side effects and risks to this procedure. First, 
you may experience mild discomfort from needle injections. You may have 
mild discomfort from intravenous infusions. Second, even though the DNA 
inserted into your lymphocytes is considered harmless to you, events could 
occur within normal cells that allow them to become cancerous. Laboratory 
studies suggest that this possibility is unlikely. However, this is a new 
procedure and we do not know whether cells could become abnormal after 
long periods of time. In animal studies, we have not observed the 
development of cancer cells in any animals tested. Third, the inserted 
DNA will contain a gene that inactivates certain antibiotics in bacteria. 
This protein is not likely to be made in humans, and many other 
Recombinant DNA Research, Volume 18 
[43] 
